Coherus Oncology (CHRS) Cash from Operations (2013 - 2026)
Coherus Oncology (CHRS) posted Cash from Operations of 57886000.0 for Q1 2026, down 193.6% sequentially from 19716000.0 in Q4 2025, and down 124.14% YoY from 239808122.55 in Q1 2025.
Coherus Oncology (CHRS) Cash from Operations (2013 - 2026) Analysis & Trends
Coherus Oncology has reported Cash from Operations for 14 years, with the latest figure at 57886000.0 in Q1 2026.
- Quarterly Cash from Operations fell 124.14% year-over-year to 57886000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 170573000.0 (down 34214.6% YoY) and the FY2025 annual result came in at 138513000.0, down 577.66% from the prior year.
- Cash from Operations eased to 57886000.0 in Q1 2026 per CHRS's latest filing, from 19716000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 59734000.0 in Q2 2024 and troughed at 99953000.0 in Q4 2022.
- A 5-year average of 37226294.12 and a median of 46632000.0 in 2025 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2024: Cash from Operations sank 26515.43% in 2022, then jumped 321.13% in 2024.
- Over 5 years, Cash from Operations stood at 99953000.0 in 2022, then soared by 87.06% to 12937000.0 in 2023, then surged by 321.13% to 28608000.0 in 2024, then plunged by 168.92% to 19716000.0 in 2025, then plunged by 193.6% to 57886000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 57886000.0, 19716000.0, and 46339000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn | -62.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -62.09 Mn |
| Jun 30, 2026 | -62.09 Mn |
| Mar 31, 2026 | -57.89 Mn |
| Mar 31, 2026 | -57.89 Mn |
| Dec 31, 2025 | -19.72 Mn |
| Dec 31, 2025 | -19.72 Mn |
| Sep 30, 2025 | -46.34 Mn |
| Sep 30, 2025 | -46.34 Mn |
| Jun 30, 2025 | -46.63 Mn |
| Jun 30, 2025 | -46.63 Mn |
| Mar 31, 2025 | -25.83 Mn |
| Mar 31, 2025 | -25.83 Mn |
| Dec 31, 2024 | 28.61 Mn |
| Dec 31, 2024 | 28.61 Mn |
| Sep 30, 2024 | -62.02 Mn |
| Sep 30, 2024 | -62.02 Mn |
| Jun 30, 2024 | 59.73 Mn |
| Jun 30, 2024 | 59.73 Mn |
| Mar 31, 2024 | -46.77 Mn |
| Mar 31, 2024 | -46.77 Mn |